This invention provides the application of agents that inhibit NNMT binding to FGFR1 in the prevention and treatment of tumors. Through
mutation analysis and interactomics analysis, it reveals a previously unknown, non-
enzyme-dependent role of NNMT in promoting aerobic
glycolysis in
breast cancer. It discovers that NNMT binds to FGFR1 and acts as a
scaffold protein, promoting
phosphorylation of PKM2 and LDHA at Y105 and Y10 sites, respectively. By positioning the FGFR1 binding interface to the 140-154
amino acid region of NNMT, this invention designs a competitive
cell-penetrating
peptide, NNMT-15, which can disrupt the NNMT-FGFR1 interaction, reduce the
phosphorylation levels of PKM2 and LDHA, inhibit
glycolysis, and suppress proliferation in NNMT-high-expressing
cancer cells and
cancer-associated fibroblasts. These findings reveal NNMT as a dual-function metabolic
regulator and establish the NNMT-FGFR1 scaffolding effect as a targeted therapeutic axis in
glycolysis-dependent tumors.